Biologic Therapies (e.g., Infliximab, Adalimumab) for Refractory Cases

Type: drug

Status: FDA Approved (for other conditions, used off-label)

Developer: Various pharmaceutical companies

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026